1. Harnden A, Takahashi M, Burgner D. Kawasaki disease. BMJ 2009;338:b1514
2. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004;114:1708–1733.
3. Royle J, Burgner D, Curtis N. The diagnosis and management of Kawasaki disease. J Paediatr Child Health 2005;41:87–93.
5. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr 2004;163:285–291.
6. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606–2612.
7. Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for nonresponse to therapy in Kawasaki disease. J Pediatr 2008;153:365–368.
9. Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006;149:237–240.
12. Kuo HC, Liang CD, Wang CL, Yu HR, Hwang KP, Yang KD. Serum albumin level predicts initial intravenous immunoglobulin treatment failure in Kawasaki disease. Acta Paediatr 2010;99:1578–1583.
13. Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Hyponatremia in Kawasaki disease. Pediatr Nephrol 2006;21:778–781.
14. Watanabe T, Abe Y, Sato S, Uehara Y, Ikeno K, Abe T. Sterile pyuria in patients with Kawasaki disease originates from both the urethra and the kidney. Pediatr Nephrol 2007;22:987–991.
15. Chiang AN, Hwang B, Shaw GC, Lee BC, Lu JH, Meng CC, et al. Changes in plasma levels of lipids and lipoprotein composition in patients with Kawasaki disease. Clin Chim Acta 1997;260:15–26.
16. Newburger JW, Burns JC, Beiser AS, Loscalzo J. Altered lipid profile after Kawasaki syndrome. Circulation 1991;84:625–631.
17. Yun SW, Lee HS, Kim DW, Rhee KW, Jung YS. Changes of lipid and lipoprotein compositions in Kawasaki disease and its impact on cardiac complications. Korean J Pediatr 2005;48:1370–1377.
18. Davis GK, Bamforth F, Sarpal A, Dicke F, Rabi Y, Lyon ME. B-type natriuretic peptide in pediatrics. Clin Biochem 2006;39:600–605.
19. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail 2005;11(5 Suppl): S81–S83.
20. Newton PJ, Betihavas V, Macdonald P. The role of B-type natriuretic peptide in heart failure management. Aust Crit Care 2009;22:117–123.
21. Sullivan DR, West M, Jeremy R. Utility of brain natriuretic peptide (BNP) measurement in cardiovascular disease. Heart Lung Circ 2005;14:78–84.
22. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, et al. NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3–8.
23. Nasser N, Bar-Oz B, Nir A. Natriuretic peptides and heart disease in infants and children. J Pediatr 2005;147:248–253.
24. Nir A, Nasser N. Clinical value of NT-ProBNP and BNP in pediatric cardiology. J Card Fail 2005;11(5 Suppl): S76–S80.
25. Dahdah N, Siles A, Fournier A, Cousineau J, Delvin E, Saint-Cyr C, et al. Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease. Pediatr Cardiol 2009;30:810–817.
26. Kawamura T, Wago M, Kawaguchi H, Tahara M, Yuge M. Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease. Pediatr Int 2000;42:241–248.